Search
Eslicarbazepine acetate
go.drugbank.com/drugs/DB09119ApprovedInvestigationalEslicarbazepine acetate is a prodrug that is rapidly converted to eslicarbazepine, the primary active metabolite in the body. … voltage-gated sodium channels, thus preventing their return to the activated state during which seizure activity can occur.
Grepafloxacin
go.drugbank.com/drugs/DB00365ApprovedWithdrawnDue to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States … Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections.
Zolpidem
go.drugbank.com/drugs/DB00425ApprovedInvestigationalThis drug decreases the time to fall asleep (sleep latency), increases the duration of sleep, and decreases the number of awakenings during sleep in patients with temporary (transient) insomnia. … This drug has the propensity to completely or partially reverse the abnormal metabolism of damaged brain cells after injury [L5584], [A175444].
Ticagrelor
go.drugbank.com/drugs/DB08816ApprovedInvestigational[A2903] It is marketed by Astra Zeneca as Brilinta in the US[L14201] and Brilique or Possia in the EU,[L14207]. Ticagrelor was granted EMA approval on 3 December 2010. … Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism.
Clenbuterol
go.drugbank.com/drugs/DB01407ApprovedInvestigationalVet approvedA substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma.
Categories: Agents to Treat Airway DiseaseEplontersen
go.drugbank.com/drugs/DB16199ApprovedInvestigationalmultiple organs, although wild-type misfolded TTR has also been observed to contribute to the disease pathophysiology. … [A262990] On December 21, 2023, the FDA approved eplontersen under the brand name WAINUA for the treatment of adult polyneuropathy of hereditary transthyretin-mediated amyloidosis.
Gemeprost
go.drugbank.com/drugs/DB08964ApprovedWithdrawnGemeprost is a prostaglandin E1 (PGE1) analog and antiprogestogen used for preoperative dilation of the cervix before surgical abortion. … It is available as vaginal suppositories and also used in combination with the antiprogestin and mifepristone for termination of 1st- and 2nd-trimester pregnancy [A19726].
Categories: Prostaglandins E, Prostaglandins E, SyntheticAvalglucosidase alfa
go.drugbank.com/drugs/DB16099ApprovedInvestigational[L39205] The EMA approved the drug on June 24, 2022.[L42720] … [A232960] On August 6, 2021, avalglucosidase alfa-ngpt was approved by the FDA under the market name Nexviazyme to treat patients one year of age and older with late-onset Pompe disease.
Pirfenidone
go.drugbank.com/drugs/DB04951ApprovedInvestigational[A251365] The FDA first approved pirfenidone alongside [nintedanib] as one of the first drugs to treat IPF.[A251165] … [A251370] While its mechanism of action is not yet fully understood, pirfenidone is proposed to primarily regulate tumor necrosis factor (TNF) pathways and modulate cellular oxidation.
Pariglasgene brecaparvovec
go.drugbank.com/drugs/DB16801Approved[L64050,L64051] It delivers a functional copy of the human G6PC gene, under the control of native G6PC promoter and enhancer elements, to hepatocytes, resulting in the production of normally functioning … [L64050] The FDA granted pariglasgene brecaparvovec-opnr accelerated approval on August 19, 2026, making it the first approved treatment for glycogen storage disease type Ia.
Synonyms: Adeno-associated viral vector serotype 8 containing the human glucose-6-phosphatase gene